CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer
Lindsay W. Brubaker(University of Colorado Anschutz Medical Campus), Benjamin G. Bitler(University of Colorado Denver)
Cited by 86
Related Papers
Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma
|Molecular Cancer Therapeutics|2022|21
Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression
|Cancer Research Communications|2024|21
Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
|Molecular Cancer Therapeutics|2022|17
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
|Molecular Cancer Therapeutics|2024|11
CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR
|Cancer Gene Therapy|2023|10